Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12-16
SponsorPhilippe Klee, MD-PhD
About this trial
The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.
Eligibility criteria
Qualifiers
Children aged 12 to 16 years
Obesity. Defined as a body-mass index above the 97th percentile.
Ability to give informed consent as documented by signature
Disqualifiers
Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8.
Patients with known liver disease (other than NAFLD)
Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion.
Patients treated with a drug known to affect liver function
Trial design
Treatments tested in this trial
- Measurement of biomarker
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Philippe Klee, MD-PhD
Lead sponsor
University Hospital, Geneva
Sponsor institution
University of Geneva, Switzerland
Collaborator
Source ClinicalTrials.gov